Skip to Content
Merck
All Photos(1)

Documents

PHR1365

Supelco

Lamivudine

Pharmaceutical Secondary Standard; Certified Reference Material

Synonym(s):

Lamivudine, 2′,3′-Dideoxy-3′-thiacytidine, 3TC, Epivir, Epivir-HBV, Heptovir, Zeffix

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C8H11N3O3S
CAS Number:
134678-17-4
Molecular Weight:
229.26
MDL number:
MFCD00869739
UNSPSC Code:
41116107
PubChem Substance ID:
329823344
NACRES:
NA.24

grade

certified reference material
pharmaceutical secondary standard

Quality Level

300

Agency

traceable to BP 802
traceable to Ph. Eur. Y0000425
traceable to USP 1356836

API family

lamivudine

CofA

current certificate can be downloaded

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC1=NC(=O)N(C=C1)[C@@H]2CS[C@H](CO)O2

InChI

1S/C8H11N3O3S/c9-5-1-2-11(8(13)10-5)6-4-15-7(3-12)14-6/h1-2,6-7,12H,3-4H2,(H2,9,10,13)/t6-,7+/m0/s1

InChI key

JTEGQNOMFQHVDC-NKWVEPMBSA-N

Looking for similar products? Visit Product Comparison Guide

Related Categories

General description

Pharmaceutical secondary standards for application in quality control, provide pharma laboratories and manufacturers with a convenient and cost-effective alternative to the preparation of in-house working standards.
Lamivudine is a synthetic nucleoside analog that shows potential action against human immunodeficiency virus (HIV). It is one of the front line therapies used to treat HIV infection.

Application

Lamivudine may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations and serum samples by chromatography and spectrophotometry techniques.
These Secondary Standards are qualified as Certified Reference Materials. These are suitable for use in several analytical applications including but not limited to pharma release testing, pharma method development for qualitative and quantitative analyses, food and beverage quality control testing, and other calibration requirements.

Biochem/physiol Actions

Lamivudine is a potent nucleoside analog reverse transcriptase inhibitor (nRTI). It is an analogue of cytidine, and can inhibit both types (1 and 2) of HIV reverse transcriptase as well as the reverse transcriptase of hepatitis B. It needs to be phosphorylated to its triphosphate form before it is active. 3TC-triphosphate also inhibits cellular DNA polymerase.

Analysis Note

These secondary standards offer multi-traceability to the USP, EP (PhEur) and BP primary standards, where they are available.

Other Notes

This Certified Reference Material (CRM) is produced and certified in accordance with ISO 17034 and ISO/IEC 17025. All information regarding the use of this CRM can be found on the certificate of analysis.

Footnote

To see an example of a Certificate of Analysis for this material enter LRAA1469 in the slot below. This is an example certificate only and may not be the lot that you receive.

Recommended products

Find a digital Reference Material for this product available on our online platform ChemisTwin® for NMR. You can use this digital equivalent on ChemisTwin® for your sample identity confirmation and compound quantification (with digital external standard). An NMR spectrum of this substance can be viewed and an online comparison against your sample can be performed with a few mouseclicks. Learn more here and start your free trial.

related product

Product No.
Description
Pricing

1356836

Lamivudine, United States Pharmacopeia (USP) Reference Standard

Y0000425

Lamivudine, European Pharmacopoeia (EP) Reference Standard

Y0000426

Lamivudine for system suitability 2, European Pharmacopoeia (EP) Reference Standard

Y0000518

Lamivudine for system suitability 1, European Pharmacopoeia (EP) Reference Standard

1356847

Lamivudine Resolution Mixture A, United States Pharmacopeia (USP) Reference Standard

1356869

Lamivudine Resolution Mixture C, United States Pharmacopeia (USP) Reference Standard

BP802

Lamivudine, British Pharmacopoeia (BP) Reference Standard

BP857

Lamivudine impurity standard, British Pharmacopoeia (BP) Reference Standard

BP850

Zidovudine and Lamivudine impurity standard, British Pharmacopoeia (BP) Reference Standard

PHR8938

Lamivudine (R)-Sulfoxide, Pharmaceutical Secondary Standard; Certified Reference Material

Pictograms

Health hazard
GHS08

Signal Word

Warning

Hazard Statements

H361

Precautionary Statements

P201 - P308 + P313

Hazard Classifications

Repr. 2

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
LRAD4236
LRAC5118
LRAA9157
LRAA1469

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Customers Also Viewed

Slide 1 of 8

1 of 8

Zidovudine United States Pharmacopeia (USP) Reference Standard

USP

1724500

Zidovudine

USP

USP

1356858

Lamivudine Resolution Mixture B

Emtricitabine Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR2120

Emtricitabine

Mefloquine Hydrochloride Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1705

Mefloquine Hydrochloride

Zidovudine European Pharmacopoeia (EP) Reference Standard

Z1900000

Zidovudine

Lopinavir Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1927

Lopinavir

Zidovudine British Pharmacopoeia (BP) Reference Standard

BP803

Zidovudine

Ritonavir Pharmaceutical Secondary Standard; Certified Reference Material

Supelco

PHR1734

Ritonavir

Determination of lamivudine and zidovudine in binary mixtures using first derivative spectrophotometric, first derivative of the ratio-spectra and high-performance liquid chromatography-UV methods
Uslu B and Ozkan SA
Analytica Chimica Acta, 466(1), 175-185 (2002)
Simultaneous determination of lamivudine and stavudine in antiretroviral fixed dose combinations by first derivative spectrophotometry and high performance liquid chromatography
Kapoor N, et al.
Journal of Pharmaceutical and Biomedical Analysis, 41(3), 761-765 (2006)
Simultaneous separation and determination of lamivudine and zidovudine in pharmaceutical formulations using the HPTLC method
Habte G, et al.
Analytical Letters, 42(11), 1552-1570 (2009)
Simultaneous determination of zidovudine and lamivudine in human serum using HPLC with tandem mass spectrometry
Kenney KB, et al.
Journal of Pharmaceutical and Biomedical Analysis, 22(6), 967-983 (2000)
Youwen Tan et al.
PloS one, 7(3), e32789-e32789 (2012-04-06)
Several recent reports have demonstrated that tyrosine (Y)-methionine (M)-aspartic acid (D)-aspartic acid (D) (YMDD) motif mutations can naturally occur in chronic HBV patients without antiviral treatment such as lamivudine therapy. This paper aims to assess the overall spontaneous incidence and
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service